Objective To discuss the factors influencing the occurrence of frailty in patients with acute myocardial infarction(AMI)after receiving interventional treatment,and to construct a prediction model,to draw a nomogram,and to make the validation of the model.Methods Using convenient sampling method,a total of 462 patients with AMI,who were admitted to the Department of Cardiovascular Medicine of three Grade Ⅲ-A hospitals in Shandong Province of China from July 2023 to January 2024,were selected as the study subjects.Among them,324 AMI patients encountered from July 2023 to November 2023 were selected as modeling group,and logistic regression was used to construct a risk prediction model and draw a nomogram to visualize the model.The remaining 138 AMI patients encountered from December 2023 to January 2024 were used as the validation group.The receiver operating characteristic(ROC)curve and Hosmer-Lemeshow testing were adopted to verify the predictive effect of the model.Results Of 324 patients in the modeling group,170(52.47％)developed frailty.Univariate analysis showed that significant differences in age,education level,body mass index(BMI),Charlson comorbidity index,grip strength,walking speed,brain natriuretic peptide precursor level,physical exercise,multiple medication,and kinesophobia existed between the two groups(all P＜0.05).Multivariate logistic regression analysis revealed that age,BMI,Charlson comorbidity index,grip strength,walking speed,NT-ProBNP precursor level,physical exercise,multiple medication,and kinesophobia were the influencing factors of frailty in patients with AMI after receiving interventional treatment,with an OR value of 1.061,0.630,1.529,0.931,0.005,0.358,1.783,2.929,and 0.497 respectively.The above nine factors were used as independent variables to draw the nomogram,the area under ROC curve of the model was 0.851(95％CI:0.809-0.892),the optimal critical value was 0.562,the sensitivity was 84.1％,and the specificity was 72.1％.Hosmer-Lemeshow goodness of fit testing showed that the model had anx2=12.957 and P=0.113.Conclusion The frailty condition of AMI patients after receiving interventional treatment is at a low to medium levels.The frailty risk prediction model constructed in this study has good prediction effect,which can provide guidance for clinical nurses to timely identify high-risk patients and to promptly adopt interventional measures.

Objective:To investigate the clinical efficacy of daggliflozin in the treatment of type 2 diabetes mellitus complicated by coronary heart disease and cardiac insufficiency.Methods:Seventy patients with type 2 diabetes mellitus complicated by coronary heart disease and cardiac insufficiency who received treatment in The Second People's Hospital of Liaocheng, The Second Hospital of Liaocheng Affiliated to Shandong First Medical University from March 2021 to February 2022 were included in this study. They were randomly divided into a control group ( n = 35) and an observation group ( n = 35). Based on conventional treatment, the control group was treated with metformin, while the observation group was treated with daggliflozin. Both groups were treated for 6 months. Pre- and post-treatment blood glucose and cardiac function as well as adverse reactions and prognosis were compared between the two groups. Results:After treatment, fasting blood glucose, 2-hour post-prandial glucose, glycosylated hemoglobin, fasting insulin, 2-hour post-prandial insulin level, left ventricular end-diastolic diameter, and peripheral blood N-terminal B-type natriuretic peptide levels in the observation group were (6.69 ± 1.83) mmol/L, (9.30 ± 2.96) mmol/L, (7.50 ± 0.98)%, (9.23 ± 2.80) mIU/L, (55.36 ± 8.38) mIU/L, (52.06 ± 5.39) mm, and (5.02 ± 1.98) μg/L, respectively, and they were (7.68 ± 2.03) mmol/L, (10.98 ± 3.33) mmol/L, (8.09 ± 1.25)%, (10.60 ± 2.26) mIU/L, (60.26 ± 8.98) mIU/L, (55.06 ± 5.86) mm, and (6.16 ± 2.28) μg/L, respectively, in the control group. There were significant differences in these indexes between the two groups ( t = 2.14, 2.23, 2.19, 2.25, 2.36, 2.22, 2.23, all P < 0.05). The left ventricular ejection fraction and 6-minute walking test in the observation group were (40.06 ± 5.26)% and (370.69 ± 52.26) m, which were significantly higher than (37.35 ± 4.33)% and (343.98 ± 38.69) m in the control group ( t = 2.35, 2.43, both P < 0.05). During the treatment period, there were no deaths in either group. Conclusion:Daggliflozin combined with conventional treatment can greatly improve glycemic control in patients with diabetes mellitus complicated by coronary heart disease and cardiac insufficiency. The combined therapy contributes to the improvement in cardiac function and is therefore worthy of promotion.